The early detection and adequate management of cardiometabolic diseases (CMD) is becoming a priority to prevent future health problems and related healthcare costs. Aim: This study systematically reviewed the economic evaluations of screening programmes for the early detection of persons at risk for CMD. Methods: A systematic review was conducted using MEDLINE, Web of Science, NHSEED and the CEA registry to identify relevant articles published between 1 January 2005 and 1 May 2015. Two reviewers independently selected articles, systematically extracted data and critically appraised the study quality using the Extended Consensus on Health Economic Criteria (CHEC) List. Results: From the initial 2820 studies identified, 17 were included. Six studies assessed whether screening would be cost-effective, seven aimed to determine the most efficient screening programme and four assessed the cost-effectiveness of existing programmes. There were 11 cost-utility analyses using quality-adjusted life years (QALYs) or disability-adjusted life years. Decision-analytic modelling (e.g. Markov model) was most frequently used (n = 10), followed by simulation models (n = 4), observational (n = 2) and trialbased (n = 1) studies. All studies assessing the cost per QALY gained of screening for cardiovascular diseases and diabetes mellitus (n = 8) were below a threshold of £30 000, while those assessing chronic kidney diseases (n = 2) were above the threshold. Conclusions: In view of the heterogeneity in study objectives, country setting, screening programmes, comparators, methodology and outcomes, it is not possible to make clear recommendations about the economic value of screening programmes for CMD. Developing further screening programmes and conducting thorough economic analysis, including usual care, is needed.
Introduction

C
ardiometabolic diseases (CMD) and cardiometabolic risk factors are emerging concepts that include conditions and factors associated with increased risk of cardiovascular disease (CVD). International working groups have defined cardiometabolic risk as an umbrella term for a comprehensive list of existing and emerging factors that predict CVD and/or diabetes mellitus (DM) and other related syndromes.
1,2 CMD, defined here in line with Badenboerk et al. 3 as CVD, DM and chronic kidney disease (CKD), are becoming a major public health problem worldwide. CMD are an increasing major cause of disability and a leading cause of death among older people. 4 Between 1990 and 2010, the total number of deaths caused by CVD increased by more than 25% and those of DM and CKD nearly doubled. 5 About 60% of deaths from these diseases are attributable to the combined effect of four cardiometabolic risk factors, including high blood pressure, high body mass index, high blood glucose and high serum cholesterol-factors that could be reduced through dietary, behavioural and pharmacological interventions. 4 Early detection and adequate management of persons at risks for CMD have, therefore, become a priority in seeking to prevent future health problems and related healthcare costs. Accordingly, in recent years, several programmes for the early detection of persons at risk for CMD have been developed and assessed in different countries.
In a world with limited healthcare resources, economic considerations play an increasingly important role in decision-making. 6 In addition to being effective in detecting people at risk and/or in preventing diseases or deaths, screening programmes for detecting persons at risk for CMD should also be cost-effective. Given the increasing prevalence and burden of CMD, there is an increasing need for economic evaluations, and some cost-effectiveness analyses have thus been performed to assess the (potential) cost-effectiveness of programmes that aim toward the early detection of persons at risk for CMD diseases.
To our knowledge, there is no overview of these studies assessing the cost-effectiveness of screening programmes for the early detection of patients with CMD. Synthesizing and reviewing the recent literature is important in order to inform decision makers about the (potential) economic value of such programmes, to identify gaps in the current evidence and to inform the development of future economic evaluations. We, therefore, undertook a systematic review of the literature to identify recent economic evaluations of screening programmes for the early detection of persons at risk for CMD in high-income countries.
Methods
Literature search
A literature search was conducted following the Centre for Reviews and Dissemination guidelines. 7 Pubmed (Ovid), Web of Science, the National Health Service Economic Evaluation Database (NHSEED) and the Cost-Effectiveness Analysis (CEA) Registry were searched to identify economic evaluations of programmes for the early detection of CMD in high-income countries. We restricted our search to articles published between 1 January 2005 and 1 May 2015, since prevalence, cost and screening programmes are changing rapidly over time.
The economic search in PubMed (Ovid) used the filter NHS QIS brief that was shown to have the best sensitivity by the Canadian Agency for Drugs and Technologies in Health. 8, 9 This filter was combined with the following additional search words: 'Mass screening (MeSH) or Primary prevention (MeSH) or Diagnostic services (MeSH) or Early diagnosis (MeSH) or Risk assessment (MeSH)' AND 'Metabolic Syndrome X (MeSH) or Cardiovascular diseases (MeSH) or Diabetes Mellitus Type 2 (MeSH) or Kidney failure, Chronic (MeSH) or Renal insufficiency' (MeSH). Human and original research filters were also applied. The same search words were used in the other databases. In addition, the references of eligible studies were searched to identify additional papers (snowball method) and citation searching was conducted for the eligible studies (forward citation tracking).
Selection of studies
The search strategy was conducted following the PICO method: population (general population/people at risk for CMD from a high-income country), intervention (screening programme), comparator (another screening programme or no programme) and outcomes (full economic evaluation defined as a comparison of at least two interventions in terms of costs and health outcomes). 10 Studies were included if they concerned screening for at least one cardiometabolic condition including CVD, DM and/or kidney disease. Titles and abstract were screened by two researchers (M.H., S.M.). Exclusion criteria were the following: not original research, not an economic evaluation, not CMD and no primary prevention. A full text review was then performed independently by two researchers (M.H. and C.W.; or M.H. and S.M.). At this stage, we included only studies that assessed screening programmes of CMD and we excluded studies from low and middle-income countries to focus on high-income countries. Disagreements were resolved by discussion in the working group with all authors.
Data extraction and quality appraisal
Data were extracted using a standardized extraction table that was piloted for two articles. Data extraction was performed by one reviewer (C.W. or M.H. or S.M.) and independently checked for accuracy by a second researcher (C.W. or M.H. or S.M.). Disagreements were resolved by discussion with the project team. Several study characteristics were included: year of publication, country, perspective of the economic evaluation, type of economic evaluation, methodology/model, sensitivity/uncertainty analyses, time horizon, discount rates, cost categories, disease, population, comparators and results. Incremental cost-effectiveness ratios (ICERs) were reported. To enable comparability across studies, all incremental ratios were converted to US$, 11 using appropriate Purchasing Power Parity (PPP) conversion rates and rated up to 2014 US$ using Consumer Price Indices (Index, 2010 = 100).
To interpret the cost-effectiveness of an intervention, we need to compare the ICER to a cost-effectiveness threshold that represents the decision maker's willingness to pay per effect unit. However, several limitations have been raised concerning the use of a single threshold. 12, 13 Therefore, most European countries do not use a threshold for cost-effectiveness, with the exception of the United Kingdom, which uses an ICER threshold range of £20 000-30 000 per QALY gained. 13 . The discussion about the use and level of ICER threshold values is ongoing in the UK. Despite potential limitations inherent in the use of a cost-effectiveness threshold, for this study, we used the threshold of£30 000 (US $42 900) in line with the threshold used by the National Institute for Clinical Excellence (NICE) in the UK.
Studies were then appraised for quality using the Extended Consensus on Health Economic Criteria (CHEC) List. 
Results
Study selection process Figure 1 shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 15 flow chart for the selection of studies. The database search identified 2820 articles, of which, 145 were excluded as duplicates. After screening by title and abstract, 76 studies were identified. At the first stage, studies were excluded mainly because they were not original research (n = 345), not an economic evaluation (n = 1891) or they did not concern CMD (n = 61) or early detection (n = 302). After reading the full text of the remaining 76 articles, six articles were excluded because they were not original studies. Ten other studies were not economic evaluations, 32 did not concern early detection of CMD and 11 were performed in developing countries. Therefore, 17 studies were included for the analysis.
16-32
Overview of included studies 22, 25, 26, 30 and three in Australia. 18, 19, 23 Eleven studies performed a cost-utility analysis (CUA), and six studies conducted a cost-effectiveness analysis. Quality-adjusted life-years (QALY) were used in ten studies and disability-adjusted life years (DALY) were used in one study for the CUA. 19 Life years gained were used as an outcome in one study. Other outcomes included event-free time, 16 the number of diabetes cases, 18 the number of diabetes cases prevented, 24 the number of screenings needed to detect one case of DM 20 and the number of high risk persons identified. 32 Model-based economic evaluations were used in 10 studies, 17, 19, 21, 23, 24, [26] [27] [28] [29] [30] of which eight applied a Markov model. Four studies used simulation models such as life tables modelling, 31,32 microsimulation 22 or the Archimedes model. 25 Two studies used observational data 16, 18 and a trial-based economic evaluation was conducted in one study. 20 Most studies used a healthcare (payer) perspective (n = 13). Only one study reported using a societal perspective 27 and one study used a combination of healthcare and societal perspectives. 24 All studies included direct medical costs; two studies additionally analysed direct non-medical costs. 24, 27 Of the two studies with stated societal perspectives, only one also incorporated indirect costs. 24 Twelve studies considered a lifetime (or long) time horizon. Two studies used a time horizon shorter than 5 years 16, 24 and two studies 18, 20 did not use a time horizon (since they focused on number of cases detected). All but one study 20 reported details on conducted sensitivity and uncertainty analyses. Fifteen studies carried out deterministic sensitivity analyses, six studies probabilistic sensitivity analyses and two studies used bootstrapping to determine the uncertainty of their results. Table 2 presents characteristics of the studied population, the interventions and comparator, and the main results of the articles. Most studies compared a screening programme to no screening/usual care. Different study aims were investigated. First, six studies aimed at assessing whether early detection (followed by management) of CMD can be cost-effective. 17, 19, 22, [26] [27] [28] Second, seven studies aimed to determine the most efficient screening programme 18, 20, 21, 23, 25, 31, 32 ; of these, three studies assessed only the screening procedure without any management intervention. 18, 20, 32 Some of these studies specifically aimed to determine the optimal screening age 25 or the cost-effectiveness of mass versus targeted screening. 20, 32 Ten studies were concerned with universal screening, five studies with targeted screening (of the high-risk population), one with opportunistic screening and one combined universal and targeted screening. Third, four studies estimated the cost-effectiveness of existing programmes for detecting CMD. 16, 24, 29, 30 Different study populations were also investigated. Nine studies assessed the cost-effectiveness of the early detection of DM, [18] [19] [20] [21] 24, 25, 27, 28, 30 while four concerned CVD or chronic heart disease (CHD), 16, 29, 31, 32 two CKD 22, 26 and two combined screening for several diseases. 17, 23 Two studies included usual care while 15 compared the intervention with no screening.
Results of included studies
All ICERs of the interventions (expressed in costs [2014 US$] per outcome) are presented in table 2. The early detection of CMD provided generally better economic results in the population at high risk 16, 20, 32 or with opportunistic screening, 20, 31 although results can differ between gender and age groups. 25, 27 In addition, figure 2 presents the ICERs for all studies (n = 10) that used QALYs as the outcome measure for estimating the cost-effectiveness of the early detection of CMD. All ICERs of early detection programmes for CVD and DM were below a threshold of US $42 900 (equivalent to £30 000) per QALY gained. 21 ,23,25,27,28,31 The two studies 22, 26 assessing the cost-effectiveness of the early detection of CKD were above a threshold of US $42 900 per QALY gained. Among the ten studies assessing the cost per QALY gained, only two studies compared universal screening with usual care.
17,23
Quality appraisal of included studies
In table 2, the total score per study can be found. The average score was 15.76 (maximum of 20), ranging from 10.50 to 18.50. In addition, Supplementary File 1 shows, for each item of the CHEC checklist, the proportion of studies with score of 1, 0.5 or 0. The economic study design was appropriate in most studies, with the exception of one study that did not include an appropriate comparison and outcome. However, only eight studies correctly reported the structural assumption and validation of the model. In five studies, competing alternatives are not clearly described and a well-defined research question is not posed in an answerable form. Furthermore, the description of the study population was not optimal in six studies, while only nine studies used an appropriate time horizon (i.e. lifetime horizon). The identification, measurement and valuation of costs as well as measurement of outcomes are generally appropriate, although some studies (between three and four per item) did not provide sufficient explanation regarding these components. Overall, an appropriate incremental analysis of costs and outcomes of alternatives was performed in the studies (12 out of 16 potential studies), and sensitivity analyses were conducted in most studies (n = 16). The conclusions follow from the data reported in all studies. However, generalizability was addressed satisfactorily in only three studies. B, bootstrapping; CHD, chronic heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DALY, disability-adjusted life-years; DM, diabetes mellitus Type 2; E, analysis of extremes; GP, general practitioner; HT, hypertension; LY, life-years; M, multivariate sensitivity analysis; P, probabilistic sensitivity analysis; QALY, quality-adjusted life-years; T, threshold analysis; U, univariate sensitivity analysis; y, years. NA, not applicable; NR, not reported. CHD, chronic heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; HT, hypertension; NA, not applicable; NR, not report.
Discussion
This review identified 17 economic evaluations of screening programmes for CMD. Most studies compared a screening programme to no screening or usual care, with only one study comparing different screening programmes. The studies differed substantially in terms of study objectives, country setting, screening type and programmes, management components, methodology and study outcomes. In view of this heterogeneity, it is not yet possible to make clear recommendations about the economic value of early detection for CMD.
In this study, we focused on studies that included early detection of CMD. Studies that assessed only the economic value of interventions for managing persons at risk for CMD without early detection were, therefore, excluded from this review. Other studies have already reviewed the cost-effectiveness of management programmes for CMD, discussing the most efficient way to manage patients with some CMD. [33] [34] [35] Based on our review and reported CUAs, it seems at first glance that the early detection of CMD, especially for DM and CVD, seems to represent good value for money using the NICE threshold for cost-effectiveness, while early detection for CKD does not seem to be cost-effective. However, the economic value could depend on the screening type and programme (an opportunistic programme appears to be more cost-effective), the management of the intervention, target population and comparator. Most CUA studies compared the programme with no screening/treatment and not to usual care as would be optimal for policy decisions. Using no screening/treatment as comparator could lead to overrating the economic value, as usual care is associated with better outcomes than no treatment. Furthermore, the number of undetected patients has diminished over time because physicians have become more alert to detecting undiagnosed patients and persons at risk for DM and CMD in their daily practice. 36 This may imply that the economic value of screening for new cases will decline. Designing and assessing further programmes for early detection and adequate management are, therefore, needed and would require a thorough economic analysis including a fair comparison with usual care. Some programmes are already in development such as the INTEGRATE study that aims to assess the (cost-)effectiveness of a CMD prevention programme coupled with an individualized lifestyle intervention. 3 Looking at the methodological quality of economic evaluations, additional points for improvement can be suggested.
Future economic evaluations should include a societal perspective, a long-term follow up and use QALY as outcome as long as no other and better measurements exists, and usual care should be included as comparator. Further studies should also better describe the structural assumptions and validation methods of the model, the population and comparator, while the generalizability of the findings should be discussed in the discussion. We also observed very few trials data, and studies were mainly model-based economic evaluation or simulation models. More well-designed trials on the effect of screening programmes would be required to adequately assess the health benefits of such programmes. Further, we did not identify any study that assessed the economic and outcomes implications of an intervention on all CMD conditions at one time.
It should also be noted that despite QALYs being the preferred outcome for economic evaluation, there is some controversy on the use of QALY, and several agencies, such as the Institute for Quality and Efficiency in Health Care (IQWiG) in Germany, do not consider QALYs in their assessment methods. 37, 38 Recently, a European study even suggested that the QALY multiplicative model is an invalid measure, which could explain why costs per QALY gained estimates may vary greatly, leading to inconsistent recommendations relevant to providing access to innovative medicines and health technologies. 39 There are some potential limitations to our study. First, we included research published in English and did not look at grey literature. In addition, since prevalence, cost and screening programmes are changing rapidly, we restricted our search to the last decade and to articles published after 2005. It could, therefore, be possible that we missed some studies, although that should not alter our conclusion. Finally, we also excluded studies from low and middle-income countries. Given different prevalence and healthcare costs, our findings may, therefore, not be generalizable to developing countries. In addition, the transferability of some countries is very uncertain, since usual care could differ widely between countries and, therefore, impact the cost-effectiveness of programmes.
In conclusion, this review identified different studies that assessed the cost-effectiveness of screening programmes for CMD and aimed to determine the most efficient screening programmes. CUAs suggest that screening programmes for DM and CVD could represent especially good value for money, while early detection for CKD seems not to be cost-effective. Unfortunately, CUAs mainly compared the screening programme to no screening/ treatment and not to usual care. In addition, opportunistic screening is associated with better economic outcomes. There is, however, a huge heterogeneity in study objectives, country setting, screening type and programmes, comparators, methodology and study outcomes. Although methodological alignment is necessary, and pivots on the use of published guidelines in order to increase comparability, it is nevertheless challenging to formulate clear and uniform policy recommendations about the economic value of the early detection of CMD across countries, given the heterogeneity of health systems among countries.
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Key points
In view of the heterogeneity in study objectives, country setting, screening types and programmes, comparators, methodology and outcomes, it is not possible to make clear recommendations about the economic value of early detection for cardiometabolic diseases. All studies (n=8) assessing the cost per QALY gained of early detection for cardiovascular diseases and diabetes mellitus were below a threshold of £30 000, while those assessing chronic kidney diseases (n=2) were above £30 000. Developing further screening programmes for the early detection of cardiometabolic diseases and conducting thorough economic analysis which includes usual care is needed in the future.
